Stay updated with breaking news from Preliminary Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 -- HUTCHMED Limited today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new...
Investegate announcements from HUTCHMED Data to be Presented at EHA2024 Congress
John Shen, MD, discusses the phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant prostate cancer.
CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of promising early pipeline New,...
Studies Demonstrate Ipsen's Ongoing Commitment to Innovation and Improving Patient Care in Neuroendocrine Tumors Paris , 28 February 2019 - Ipsen today announced that...